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CHRONIC VAGUS NERVE STIMULATION REDUCES BODY FAT, 
BLOOD CHOLESTEROL AND TRIGLYCERIDE LEVELS 
IN RATS FED A HIGH-FAT DIET
Abstract: Chronic vagus nerve stimulation reduces body fat, blood cholesterol and triglyceride levels 
in rats fed a high-fat diet
There is growing evidence that vagus nerve stimulation (VNS) exerts a suppressive effect on both 
short- and long-term feeding in animal models. We previously showed that VNS with high-frequency 
(10 Hz) electrical impulses decreased food intake and body weight in rats. In the present study, we 
investigated the effect of VNS with a low frequency (1 Hz) on the serum lipid concentrations, feeding 
behavior and appetite in rats fed a high-fat diet. The levels of appetite-regulating peptides were also 
assessed.
Adult male Wistar rats were subcutaneously implanted with a microstimulator (MS) and fed 
a high-fat diet throughout the entire study period (42 days). The left vagus nerve was stimulated 
subdiaphragmatically by rectangular electrical pulses (10 ms, 200 mV, 1 Hz, 12 h a day) generated 
by the MS. The daily food intake and body weight were measured each morning. At the end of the 
experiments, the serum glucose, cholesterol, triglycerides, low-density lipoproteins, high-density li-
poproteins, ghrelin, leptin and nesfatin-1 concentrations were measured. The adipose tissue content 
was evaluated by the assessment of the weight of the epididymal fat pads.
Chronic VNS significantly decreased food intake, body weight gain and epididymal fat pad we-
ight. VNS also lowered the total plasma cholesterol concentrations and triglyceride levels. Finally, 
the serum concentrations of nesfatin-1 were elevated, leptin levels were decreased, and ghrelin levels 
remained unchanged after VNS.
The study demonstrates that chronic electrical VNS exerts anorexigenic effects, lowering the blood 
concentration of lipids. Increased nesfatin-1 levels may contribute to these effects.
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INTRODUCTION
Vagus nerve stimulation (VNS) is an alternative therapy to treat epilepsy and 
depression [1, 2]. It has also been under investigation for the management of 
various anxiety disorders [2], Alzheimer’s disease, migraines [3], fibromyalgia [4], and 
tinnitus [5]. Moreover, the stimulation of the vagus nerve tends to increase the 
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production of anti-inflammatory cytokines and thus may lead to the increased rate 
of survival in experimental sepsis, hemorrhagic shock and ischemia–reperfusion 
injury models [6–9]. In such vagus nerve manipulations, VNS therapy has been 
surprisingly shown to induce, at least in some cases, alterations in food intake and 
weight decreases. These findings have encouraged many researchers to investigate 
the possible mechanisms of the weight loss after vagus nerve stimulation and to 
launch it as a possible new method for obesity treatment [10, 11].
Body weight, food intake and body fat content are regulated by multiple factors 
and controlled by short- and long-term regulation mechanisms. Food transported 
into the stomach and duodenum activates chemo- and mechanoreceptors, and 
these signals are transferred via the vagus nerve to the hind brain, where they 
are integrated and play a major role in the short-term regulation, reducing the 
size of meal consumed [12, 13]. Using extracellular recordings from the vagus 
nerve, Randich and Cox [14, 15] showed that the vagus conducts “satiety signals” 
from the jejunum when activated by fatty acid infusion. In the long–term control 
of food intake, the roles of various other mediators (ghrelin, leptin, nesfatin-1, 
orexins, neuropeptide Y) and structures (vagal afferent neurons — VAN, arcuate 
nucleus of vagus nerve — ARC, hypothalamus) must also be considered [13]; 
however, the vagal afferents play an essential role in such a regulatory system.
Thus, decreased food intake and weight gain in the animal models with vagus 
nerve stimulation must be considered as the result of the stimulation of brain 
centers, peripheral actions of vagal stimulation via short cholinergic reflexes and 
the combination of central and peripheral signals [13]. The VNS decreases food 
intake and body weight gain by signals transmitted from the gut to the brain, 
leading to the activation of the hypothalamic neurons and resulting in the state 
of satiety. Because vagal afferents transmit information to the brain not only from 
activated mechanoreceptors of the gastrointestinal tract but also from duodenal 
chemoreceptors, hepatic glucoreceptors and osmoreceptors [16], this hypothesis 
appears to have strong support.
We previously showed that short-term vagus stimulation affects food intake 
and decreases body weight in rats [17, 18]. Furthermore, Bugajski et al. [19] 
reported decreases in meal size, body weight and epididymal fat pad weight in 
obese rats. These data were confirmed by our recent work performed in rats fed 
a high-fat diet. The animals stimulated during a 6-week period with left VNS (10 Hz) 
revealed significant decreases in food consumption and body weight gain, lower 
fat accumulation and elevated levels of the anorexigenic peptide nesfatin-1 [20]. 
Moreover, VNS evoked changes in the nodose ganglia of the vagus nerve, affirming 
the afferent signal transmission of VNS signals [21]. Simultaneously, Ziomber 
et al. [22] showed that modulation of the left vagus by MS placed in rats with 
magnetic field exposure led to a decrease in body weight gain in growing animals 
and that this effect was correlated with a decrease in the leptin serum level. 
Disappointingly, in humans subjected to VNS, no changes in body weight were 
81
observed [23, 24], or the data were controversial [25, 26]. Thus, the appropriate 
frequency, amplitude of impulses and character of the stimulation still need to 
be established in experimental models.
As the left and right vagal trunks feed different parts of the gastrointestinal 
tract and the contribution of both is important, the decision of which trunks 
should be stimulated remains controversial. Some previous works from our 
laboratory [17, 18] demonstrated that bilateral VNS seems to be more effective 
than unilateral stimulation, but others proved that unilateral stimulation could 
also be effective. However, to limit the possible side effects on the heart or 
lungs, we decided to apply chronic VNS by a microstimulator placed on the left 
vagus nerve. Electrodes were placed close to the gastro-esophageal junction to 
stimulate the small unmyelinated C fibers and avoid stimulating the fibers that 
join the trunk from the heart and lungs, as discussed by Val-Laillet et al. [27]. 
We used constant voltage microstimulators implanted for at least 6 weeks and 
used an intermediate frequency of stimulation at 1 Hz. Vagus nerve stimulation at 
a high frequency (20–30 Hz) was previously hypothesized to act mainly on 
the vagal afferents, influencing the brain centers, whereas the low-frequency 
(less than 5 Hz) VNS targets predominantly vagal efferents, evoking mainly anti-
inflammatory effects [28]. Our previous experiments showed that VNS with 10 Hz 
exerts anorexigenic effects in rats fed a high-fat diet. Consequently, the aim of 
the current study was to evaluate the effects of chronic left VNS with a low (1 Hz) 
frequency on the long-term regulation of body weight and food intake in rats fed 
a high-fat diet. The serum glucose, cholesterol, triglyceride, low-density lipoprotein 
(LDL) and high-density lipoprotein (HDL) concentrations were also measured. 
The development of obesity after a high-fat diet in this animal model has been 
already described and documented [19, 22, 29]. Furthermore, we evaluated the 
fat compartment of the experimental rats by measuring the epididymal fat pad, 
which reflects the total body fat mass [30]. We also investigated the blood levels 
of some appetite-regulating hormones, ghrelin, leptin and nesfatin-1, as they are 
known to play an important role in both the short- and long-term regulation of 
food intake.
MATERIAL AND METHODS 
ANIMALS
Thirty-two male Wistar rats, housed in individual cages, were used in the 
experiment. Twenty-four animals were fed a high-fat diet (caloric distribution of 
the diet: protein 25.1%, fat 38.8%, carbohydrates 36.1%, metabolizable energy 
4.34 kcal/g; Bento Kronen Products, Belgium) during the whole experiment, and 
eight rats were fed with the standard diet (caloric distribution of the standard diet: 
protein 26.7%, fat 7.9%, carbohydrates 65.4%, metabolizable energy 2.86 kcal/g; 
Labofeed, Poland).
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The temperature was maintained at 23 ± 2oC, and the animals were placed 
on a 12 : 12 h dark/light cycle. Food and water were provided ad libitum. The 
Jagiellonian University Bioethical Committee approved the care and use of the 
animals (protocol number — 36/2008).
After 2 weeks of adaptation to the environmental conditions and the fat diet, 
the rats were starved for 12 hours and were operated under general anesthesia 
induced with sodium pentobarbital given intraperitoneally (Vetbutal, 0.25 mg/kg, 
Biowet, Pulawy, Poland). The rats were randomly divided into the following groups: 
(1) rats with an active microstimulator (MS) connected by electrodes to the left 
vagal nerve (MS group, n = 8), (2) animals with inactive MS without electrodes on 
the vagal nerve (sham group, n = 8), (3) intact rats without the MS and electrodes 
(control group, n = 8), and (4) rats fed the standard diet without the MS and 
electrodes (standard group, n = 8). The control group of animals (intact rats) was 
included in the study to eliminate any effects of the surgical procedures on the 
examined parameters. The group of animals fed the standard diet was included 
in the study to compare the effects of the high-fat diet on the rats. The sham-
operated group served as the most important reference group for the assessment 
of food intake, body weight and epididymal fat pad weight.
ExPERIMENTAL PROTOCOL
The MS for vagus chronic stimulation (designed by the Institute of Electron 
Technology, Krakow, Poland) was sealed with silicone (Sylgard® 184 Silicone Elasto-
mer, Dow Corning Co., Midland, MI, USA) placed during the surgery into the 
subcutaneous pocket. The electrodes of the MS were made from insulated silver 
wire (A-M Systems, Carlsborg, WA, USA). The unisolated ends of the electrodes were 
wrapped around the subdiaphragmatic left vagal nerve. The cathode and anode 
were positioned at a 0.5 cm distance. In the second group, a laparotomy was 
performed, and the inactive MS was implanted (sham group). In the control group 
(intact), no surgical manipulations were performed. Food was restored on the day 
after the operation. After a 1 week recovery period, the rats were placed into 
cages with electromagnetic field exposure, and the stimulation was started (day 1st).
The animals from the MS and sham groups were placed individually into 
plastic cages and exposed to the magnetic field. The cages were connected to the 
generator of sinusoidal waves with an amplifier (Neurostimulator NSE 002, Electron 
Technology Institute, Krakow, Poland), and a 30 kHz pulsating magnetic field 
was generated. The magnetic field served as an external source of current in the 
MS wires connected to the left vagus nerve. The theoretical background for this 
method has been described by Zaraska et al. [31]. The parameters of the magnetic 
field were set experimentally to match the amplitude, duration and frequency of 
impulses used in our experiment. The third (control) and fourth (standard) groups 
of rats were placed into cages outside the magnetic field. The parameters of the 
impulses generated by MS were based on our previous studies and set as follows: 
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unipolar rectangular pulses, duration 10 ms, amplitude 200 mV, and frequency 
1 Hz. The stimulation of the animals started every day at 6 p.m. and lasted 
12 h until 6 a.m. the following morning (dark phase stimulation) during the whole 
experiment because food intake is predominantly nocturnal in rats and the 
amount of food consumed during the light phase does not exceed 10% [32].
The daily food intake and body weight were measured each morning during the 
entire study. The amount of the daily food intake was determined by subtracting 
the amount of food remaining from the amount given 24 h before. At the end of 
the experiment (day 42nd), immediately after the stimulation stopped, all the rats 
(non-fasted) were killed by decapitation and weighed. Both epididymal fat pads, 
located between the cauda epididymis and the distal extremity of the testis, were 
dissected from the animal and weighed. The epididymal fat pad/body weight ratio 
was calculated by dividing the fat pad weight by the total body weight.
BIOCHEMICAL ANALYSIS
Blood samples collected at the end of the experiment were taken into tubes 
containing aprotinin (0.6 TIU per 1 ml of blood; Sigma-Aldrich, USA), which 
were left for 30 minutes for clot formation. After centrifugation at 1500 ×g for 
20 min at 4oC (Megafuge 1.0R, Heraeus Instruments), the serum samples were 
collected and frozen at –80oC until further analysis. Serum aliquots were prepared 
from each sample, and the glucose, hepatic enzymes (aspartate and alanine 
transaminases), triglyceride, total cholesterol, LDL and HDL levels were measured 
with the chemistry immune-analyzer, Olympus AU 600. Three serum aliquots 
were prepared, and the ghrelin, leptin, and nesfatin-1 levels were measured by 
the radioimmunoassay method (RIA), according to the protocols provided by 
the manufacturer (Phoenix Pharmaceuticals Inc., USA). All measurements were 
performed in duplicate.
STATISTICAL ANALYSIS
The data are expressed as the means and standard deviation (SD). The results 
were analyzed by one-way analysis of variance (ANOVA), followed by the post-
hoc LSD test, with the STATISTICA 8.0 software package (StatSoft, Tulsa). The 
statistical significance was set at P < 0.05.
RESULTS
FOOD INTAKE AND BODY WEIGHT
In rats fed the high-fat diet, the food intake, body weight and epididymal fat pad 
weight were significantly increased compared with the animals fed the standard 
diet (Table 1).
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Electrical stimulation of the left vagal nerve reduced the total food intake 
in the MS group compared with the sham and control groups. The differences 
were significant (P = 0.02 MS vs. sham; P = 0.04 MS vs. control). No differences 
between the sham and control groups were observed (P > 0.05; Table 1).
Although the final body weight was not significantly different in the MS group 
compared with the unstimulated and control animals, the VNS significantly 
reduced the body weight gain. The mean body weight gain in the MS group 
was 25.6% of the initial body weight, but it was 30.7% in the sham group and 
28.7% in the intact group. Neither the high-fat diet nor VNS influenced the feed 
conversion efficiency. The amount of the total calorie intake during the experiment 
was significantly increased in the animals fed the diet rich in fat compared with 
the rats fed the standard diet.
T a b l e  1
Mean food intake, body weight and epididymal fat pad weight in MS left vagus nerve stimulation 
(1 Hz), sham operated, control (intact)and standard rats
Sham MS-1 Hz Control Standard
Food intake during 
experiment (g)
  1025 ± 65  891 ± 89*  1042 ± 78   1210 ± 89
Food intake during 
experiment (kcal)
4448 ± 282  3867 ± 386* 4522 ± 338 3436 ± 254
Feed conversion efficiency 
# (kcal/g)
28.1 28.6 30.1 30.9
Initial body weight (g) — 
day 1
516.5 ± 43,0 526.9 ± 24.4 524.8 ± 64.8 526.5 ± 25.2
Sham MS-1 Hz Control Standard
Final body weight (g) — 
day 42
675.0 ± 69.4 662.7 ± 30,0 700.3 ± 67.8    629 ± 22.7
Body weight gain (g) 158.5 ± 27,0  135.9 ± 8.9* 150.5 ± 50.4 111,3 ± 19.5
Body weight gain 
increment over initial body 
weight (%)
30.7 25.6* 28.7 20.8
Epididymal fat pad weight 
— EFP (g)
  14.5 ± 3.52  11.6 ± 1.5* 15.0 ± 2.6 11.3 ± 2.6
EFP/body weight ratio (‰) 21.3 ± 3.3  17.6 ± 2.8* 21.3 ± 2.2 17.4 ± 4.4
Asterisks (*) indicate significant differences between the MS-1 Hz group and the sham and control groups.
# the feed conversion efficiency was measured as the total food intake expressed in kcal divided by the weight gain 
for each animal during the experiment [33].
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EPIDIDYMAL FAT PAD WEIGHT
The fat pad weight, reflecting the total body fat content, was significantly higher 
in the sham group than in the MS group (P = 0.036). For the control group, the 
fat pad weight was also significantly higher than that in the MS group (P = 0.04). 
The mean epididymal fat pad weight relative to the body weight (fat pad/body 
weight ratio) was significantly lower (17.6‰) for rats with active MS compared 
with the sham animals (21.3‰) and the control animals (21.3‰) (Table 1). No 
differences between the sham and control groups were observed.
BLOOD BIOCHEMICAL ANALYSES
There were no significant differences between the VNS-treated rats and the sham, 
control, and standard rats with respect to the level of glycemia and the levels of 
aspartate and alanine transaminases. The high-fat diet significantly influenced 
the blood lipid composition by elevating the levels of triglycerides, total cholesterol, 
high-density lipoproteins and low-density lipoproteins (Table 2). VNS considerably 
reduced the blood triglyceride levels compared with the sham (P = 0.025) and 
control (P = 0.040) groups (Figures 1 and 2). The total serum cholesterol levels were 
significantly lower in the rats with active MS than in the sham animals (P = 0.045) 
and control animals (P = 0.032). The HDL concentrations remained unchanged, 
whereas VNS slightly, but not significantly, lowered the LDL cholesterol levels.
T a b l e  2
The blood serum levels of glucose, triglycerides, total cholesterol (TC), high-density lipoproteins (HDL), 
low-density lipoproteins (LDL), and aspartate (AspAT) and alanine (AlAT) transaminases in MS left 
vagus nerve stimulation (1 Hz), sham operated, control (intact) and standard rats
Sham MS-1 Hz Control Standard
Glucose (mmol/L) 7.71 ± 0.49  7.72 ± 0.42 8.11 ± 0.69 7.37 ± 1.11
Triglycerides (mmol/L) 2.32 ± 1.30 1.86 ± 0.58 *   2.0 ± 0.34 1.41 ± 0.75
TC (mmol/L) 2.26 ± 0.21 2.04 ± 0.48 * 2.39 ± 0.17 1.89 ± 0.27
HDL (mmol/L) 0.95 ± 0.08  0.97 ± 0.11 1.12 ± 0.10 0.89 ± 0.12
Sham MS-1 Hz Control Standard
LDL (mmol/L) 0.57 ± 0.21 0.49 ± 0.09 0.57 ± 0.10 0.35 ± 0.23
AspAT (UI/L)   153 ± 19   186 ± 17   160 ± 28   170 ± 53
AlAT (UI/L) 68 ± 10     60 ± 7 65 ± 11 67 ± 17
Asterisks (*) indicate significant differences between the MS-1 Hz group and the sham and control groups.
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Fig. 1. Triglyceride blood serum concentration after left vagus nerve stimulation (MS-1 Hz) with the 
frequency of 1 Hz in the sham, control and standard groups (n = 8 for each group). The triglyceri-
de level decreased in the MS-1 Hz group. Data are presented as the mean and standard deviation. 
*P < 0.05 compared with the sham and control groups
Fig. 2. Total cholesterol blood serum concentration after left vagus nerve stimulation (MS-1 Hz) with 
the frequency of 1 Hz in the sham, control and standard groups (n = 8 for each group). The cholesterol 
level significantly decreased in the MS-1 Hz group. Data are presented as the mean and standard 
deviation. *P < 0.05 compared with the sham and control groups
sham              MS-1 Hz              control             standard
sham              MS-1 Hz              control             standard
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GHRELIN
There were no significant differences in the ghrelin serum levels between the 
VNS-treated rats and the sham, control, and standard rats (352.9 ± 72.9 pg/mL 
in the MS group, 411.7 ± 68.8 pg/mL in the sham group, 357.2 ± 73.1 pg/mL 
in the control and 352.2 ± 42.2 pg/mL in the standard group). Neither the high-
fat diet nor VNS influenced the serum ghrelin level in the experimental animals.
LEPTIN
The high-fat diet elevated the leptin serum levels in the examined groups, especially 
the control and sham groups. The leptin serum level was significantly decreased 
in the VNS group compared with the sham (P = 0.007) and control (P = 0.013) 
groups (9.274 ± 2.39 ng/mL in the stimulated group, 11.5 ± 1.82 ng/mL in the 
sham group, 13.3 ± 3.66 ng/mL in the control and 8.73 ± 1.3 ng/mL in the 
standard group; Figure 3). No differences between the sham and control groups 
were found.
Fig. 3. Leptin serum concentration after left vagus nerve stimulation (MS-1 Hz) with the frequency of 
1 Hz in the sham, control and standard groups (n = 8 for each group). The leptin level significantly 
decreased in the MS-1 Hz group. Data are presented as the mean and standard deviation. 
*P < 0.05 compared with the sham and control groups
sham             MS-1 Hz             control             standard
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NESFATIN-1
The high-fat diet lowered the nesfatin-1 serum levels in the examined animals. 
Vagus nerve stimulation significantly increased the nesfatin-1 serum level 
compared with the sham (P = 0.009) and control (P = 0.01) groups (990.1 ± 221 
pg/mL in the stimulated group, 784.5 ± 273.4 pg/mL in the sham group, 766.25 
± 146.8 pg/mL in the control and 1026.3 ± 219.1 pg/mL in the standard group; 
Figure 4). No differences were found between the sham and control groups.
Fig. 4. Nesfatin-1 serum concentration after left vagus nerve stimulation (MS-1 Hz) with the frequency 
of 1 Hz in the sham, control and standard groups (n = 8 for each group). The nesfatin-1 level signi-
ficantly increased in the MS-1 Hz group. Data are presented as the mean and standard deviation. 
*P < 0.05 compared with the sham and control groups
DISCUSSION
Vagus nerve stimulation is a relatively new method adopted for obesity treatment. 
So far, the exact mechanism of the reduction in body weight has remained 
unclear. This animal study was performed using a high-fat diet because obesity 
induced by high-fat diet mimics obesity in humans and is widely considered an 
appropriate model for studying dietary obesity [34–36). However, the use of such 
a diet evokes significant changes in the appetite regulating-peptide levels. 
A high-fat diet increases, but fasting decreases, the nesfatin-1 protein levels and 
secretion by adipose tissue, and a positive correlation between the body mass 
index and circulating nesfatin-1 levels in humans has been reported [37, 38]. As 
for leptin, a short-term, high-fat diet lowers the circulating leptin concentration 
sham             MS-1 Hz             control             standard
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[39], whereas in animals fed a high-fat diet for a long time, a significant increase 
in the leptin levels is present [40, 41]. The ghrelin concentration decreases after 
feeding with diets rich in fat [40, 42]. Thus, the experimental results may differ as 
they depend on the animal model applied, and the results should be considered 
with caution.
We showed previously that low frequency VNS affects the short-term volume 
regulation of food intake and decreases the body weight in rats [17, 18], but 
these experiments were performed in rats fed the standard diet. Furthermore, 
we reported a significant decrease in body weight and food consumption after 
left VNS with a 10 Hz frequency in rats fed a high-fat diet [20]. Those data 
encouraged us to examine whether such effects could be evoked by VNS with a 
lower frequency (1 Hz). Our hypothesis appeared to be correct, although the 1-Hz 
stimulation seems to be less effective than VNS with 10 Hz. There were significant 
decreases in the food intake, body weight gain and epididymal fat pad weight in 
animals treated with chronic vagus nerve stimulation with the microstimulator 
set at 1 Hz compared with the sham and control animals. We also examined the 
effects of VNS on the feed conversion efficiency. The VNS-treated rats required an 
intake of approximately 30 kcal to gain 1 g of weight. No differences were found 
among the groups of animals used in our experiment. Conversely, Banni et al. 
[33] observed a significantly decreased feed conversion efficiency by chronic VNS, 
suggesting that peripheral mechanisms may be involved in weight loss after VNS. 
Our data did not support their conclusions.
Most of the VNS studies performed on rats showed either a decrease in body 
weight gain or weight loss [19, 22, 29]. Similar observations were reported in 
growing pigs by Matyja et al. [43], Val-Laillet et al. [27], and Sobocki et al. [44] 
and in rabbits by Sobocki et al. [45]. Some studies revealed other effects of VNS: 
activation of different brain structures [46], decrease in plasma insulin growth 
factor — 1 (IGF-1) concentration [44], altered myoelectric activity [43] or increase 
in gastric emptying and increase in the amplitude of gastric contraction [19]. 
The effects of vagus nerve stimulation on body weight and food consumption 
observed in several animal models indicate that this vagal manipulation may 
evoke satiety signals that are normally transmitted toward the brain centers 
controlling appetite, body weight and adipose tissue accumulation. The use of 
different models of stimulation (time, voltage, and species of animals) limits the 
benefits of these results. However, this growing knowledge of VNS from basic 
studies allowed some pilot clinical studies to be started [10, 11].
In long-term VNS (0.05 Hz, 102 days) in obese rats fed a high-fat diet performed 
by Bugajski et al. [19], a decrease in weight loss resulting from diminished food 
intake and the reduction of the body fat compartment, as measured by the fat pad 
mass, were reported. Similar results published by Ziomber et al. [22] in growing 
rats, using a different frequency of stimulation (0.1–1.0 Hz) and an amplitude 
ranging from 50 to 200 mV, resulting in a decreased body weight gain of the rats 
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examined. An interesting study concerning the relationship between vagus 
stimulation and appetite was published by Val-Laillet et al. [27]. The authors 
performed bilateral VNS with current stimulators (2 mA, 30 Hz, 500 µs pulse, 
ON 30 s, OFF 5 min) on obese mini-pigs. The VNS animals did not significantly 
gain weight compared with the sham animals, food consumption was decreased 
by 18% in the VNS mini-pigs, and sweet-food consumption was also diminished 
compared with the sham animals; these effects lasted for more than 14 weeks. 
It should be mentioned here that Val-Laillet used current stimulation instead of 
constant voltage stimulation to avoid possible, additional voltage drops, decreasing 
the current at the nerve level and potential insufficiency for stimulation [47]. However, 
our data showed that VNS increases the c-Fos positive neurons in the nodose 
ganglion of the left vagus nerve (stimulated) [21], in the nucleus of the solitary 
tract [20] and in the arcuate nucleus of the hypothalamus (yet unpublished results). 
Moreover, the study by Helmers et al. [48] proved that the range of output current 
settings between 0.75 and 1.75 mA with pulse width settings of 250 or 500 µs 
may result in optimal stimulation. Thus, we may conclude that constant voltage 
stimulation with the parameters used in our model is sufficient and effective.
Visceral fat or abdominal fat is located inside the abdominal cavity, packed 
between the organs. Visceral fat is composed of several adipose depots, including 
mesenteric, epididymal white adipose tissue and perirenal depots. Visceral fat is 
considered to be adipose tissue, whereas subcutaneous fat is not considered as 
such. An excess of visceral fat is known to be related to the grade of obesity. 
In rodents, one of the particular regions where visceral fat accumulates is the 
epididymal fat pad. The epididymal fat pads represent only a small part of the 
total body weight, but previous studies showed that the epididymal fat pad weight 
calculated as a proportion of the total body weight is highly correlated with the 
total body fat in mice and rats [30]. In our experiment, the body composition 
was altered by vagus nerve stimulation: the epididymal fat pad mass relative to 
body weight was significantly lower in rats with VNS compared with the control 
and sham animals. This observation correlated with data from previous studies 
[19, 20, 29]. Such a decrease in fat depots corresponds to the lowered food 
consumption and diminished weight gain caused by VNS. Furthermore, the blood 
cholesterol and triglyceride levels were significantly reduced. These effects were 
caused, in our opinion, by a reduced calorie intake. Other peripheral effects of 
VNS, such as increased lipid metabolism or excessive energy spending, are not 
excluded but are unlikely because VNS did not influence the feed conversion 
efficiency. However, VNS opens new possibilities for the treatment of excessive 
blood lipid contents connected to obesity.
The significant decrease in the fat content in the VNS-treated rats is related to 
the changes in appetite and regulating peptide concentrations, especially leptin. 
Most of the published reports are consistent with the correlation of the leptin 
expression and its release with the amount of body fat and number of adipocytes, 
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and its blood concentration mainly depends upon the adipose tissue content 
as this peptide is generated by fat cells [49, 50]. Indeed, in our experiment, we 
observed a significant leptin decrease after VNS, correlating with a decreased 
weight gain and reduction in food consumption. It is well documented that leptin 
is involved in the regulation of feeding behavior and energy expenditure [50, 51]. 
Leptin decreases food intake under the physiological condition. However, obesity 
in humans is generally associated with leptin resistance, which is progressively 
established during a hypercaloric diet and accompanied by a progressive increase 
in the serum leptin levels [49], and the leptin level in this group remains high. 
It should also be mentioned here that vagus nerve circuits play a role in leptin 
secretion. In 2003, Cigaina et al. reported that a decrease in the leptin level 
significantly correlated with weight loss in patients with gastric pacing [52]. Wang 
et al. [53] did find any changes in the leptin level either after vagus nerve dissection 
or after gastric bypass in rats. However, the leptin concentration was significantly 
diminished and correlated with weight loss in both studies. Recently, De Lartigue 
et al. [54] demonstrated that diet-induced obesity led to the development of leptin 
resistance in vagal afferent neurons (VAN) and that leptin signaling in VAN is 
required for appropriate cholecystokinin signaling and satiation, limiting meal size 
and duration [55]. In previous studies [20, 22], we reported that the rats with 
vagus nerve stimulation have decreased plasma leptin concentrations. If VNS 
reduces food intake by leptin release, we would expect an increase in the leptin 
concentration, but we have obtained the opposite results. We conclude that the 
observed decrease in the leptin concentration after VNS is associated with the 
diminished body weight gain and loss of the adipose tissue content rather than 
with the vagus nerve manipulations.
Ghrelin, a peptide produced predominantly in the stomach and duodenum, 
evokes an orexigenic effect, increasing food intake in both animals and humans 
[56]. The mechanism of action involves the vagus nerve and activation of neurons 
in the hypothalamus [57, 58]. The ghrelin level increases before a meal and 
sharply falls after the start of the meal, suggesting a possible role in the induction 
of a meal [59]. Moreover, the systemic ghrelin level is negatively correlated with 
body weight and adiposity and increases with weight loss, whereas weight gain 
leads to decreased systemic ghrelin levels [60]. Ghrelin administration leads to 
weight gain in experimental animals by stimulating food intake, decreasing energy 
expenditures and spontaneous activity and promoting adipogenesis [61]. Obese 
individuals have decreased ghrelin levels [62], which can be normalized after 
diet-induced weight loss [63].
We previously reported an increase in the ghrelin serum concentration after 
electrical vagus nerve stimulation with the frequency at 10 Hz [20]. Data from the 
current study, however, did not confirm such an observation. Work by Cigaina 
et al. [64] and Gallas et al. [65] described an increase in the ghrelin plasma 
concentration after gastric stimulation. Although gastric pacing does not directly 
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stimulate the vagus nerve, the authors postulated the involvement of the vagus 
nerve in ghrelin release after gastric pacing. In contrast, Li et al. [66] revealed 
that gastric electrical stimulation in diet-induced obese rats reduced food intake, 
body weight and gastric emptying but that the peripheral modulation of plasma 
ghrelin level was not related to the stimulation effects. Although such results 
are not entirely conclusive, we may suggest that the observed reduction in the 
body weight and inhibition of food intake after VNS are due to other mechanisms 
rather than ghrelin mediators or metabolic pathways.
Nesfatin-1 is an 82 amino acid anorexigenic peptide derived from its precursor 
protein, NEFA/nucleobindin2 (NUCB2), which was identified by Oh [67]. Nesfatin-1 
administered into the third cerebral ventricle significantly reduces food intake in 
rats. Twenty-four-hour fasting effectively reduces the NUCB2 expression in the 
paraventricular nucleus (PVN) [68], and nesfatin-1 immunopositive neurons in the 
PVN are activated by refeeding [69], indicating that nesfatin-1 plays an important 
role as a regulator of food intake. Nesfatin/NUCB2-immunopositive neurons are 
also located in the arcuate nucleus (ARC) and co-localize with proopiomelanocortin 
(POMC) and CART (Cocaine-and-Amphetamine Responsive Transcript) neurons 
[67, 68]. Nesfatin-1 crosses the blood–brain barrier in both the blood to brain and 
brain to blood directions [70, 71]. As reported by Shimizu et al. [72], nesfatin-1 
given peripherally (by intraperitoneal injection) diminished the food intake. The 
study by Stengel et al. showed that nesfatin-1-immunopositive cells are present 
in the rat gastric mucosa and that most of the nesfatin-1-immunopositive cells 
also co-expressed ghrelin [73]. Moreover, the down-regulation of NUCB2 mRNA 
in gastric endocrine cells after 24-h fasting proved that nesfatin/NUCB2 gene 
expression might be regulated by the nutritional status. That mechanism was 
elucidated by Li et al., who examined nesfatin-1 level fluctuations in diabetes 
mellitus patients after oral glucose ingestion [74]. He observed the reduction in the 
fasting nesfatin-1 concentration, which in his opinion may be one of the appetite-
related hormones involved in diabetic hyperphagia. However, glucose ingestion 
did not affect the plasma nesfatin-1 level, suggesting that gastric chemosensation 
is not sufficient for the nesfatin-1 response. Tan at al., in a study on obese 
patients, found that the increase in the nesfatin-1 level correlated positively with 
body mass index (BMI) and fat mass in obesity and also observed that plasma 
nesfatin-1 was negatively correlated with nesfatin-1 in the cerebrospinal fluid, 
suggesting nesfatin-1 resistance in obese subjects [75].
In our experiment, the nesfatin-1 level was significantly elevated after vagus 
nerve stimulation. Thus, we suggest that vagus nerve stimulation increases the 
nesfatin-1 serum concentration, causing the anorexigenic effects observed in our 
study. The data from studies by Shimizu et al. partially support our hypothesis, 
as intraperitoneally administered M30, the active mid-segment of nesfatin-1, 
induced anorexia via the vagus nerve in mice whereas this effect was abolished 
in capsaicin-pretreated animals [76].
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The present study demonstrates that food intake and body weight gain are 
decreased by long-term VNS at 1 Hz in rats fed a high-fat diet, leading to decreased 
levels of cholesterol and triglycerides. These data support our hypothesis that 
the electrical signals generated by a microstimulator and conducted by vagal 
afferents as satiety signals can modify the central regulation of body weight, 
food intake and body fat content. VNS causes changes in the nesfatin-1 levels, 
which may contribute to observed reductions in body weight and fat. Vagus nerve 
neuromodulation opens new possibilities for obesity management.
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